Vanzacaftor/tezacaftor/deutivacaftor

Vanzacaftor/tezacaftor/deutivacaftor
Combination of
VanzacaftorMedication
TezacaftorMedication
DeutivacaftorCFTR potentiator
Clinical data
Trade namesAlyftrek
AHFS/Drugs.comMonograph
MedlinePlusa625066
License data
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
KEGG

Vanzacaftor/tezacaftor/deutivacaftor, sold under the brand name Alyftrek, is a fixed-dose combination medication used for the treatment of cystic fibrosis. It is a combination of deutivacaftor, a CFTR potentiator; tezacaftor; and vanzacaftor, as the calcium salt, vanzacaftor calcium dihydrate. It is taken by mouth.

The combination was approved for medical use in the United States in December 2024, in the European Union in June 2025, and in Canada in July 2025.

This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.